We have located links that may give you full text access.
Association of midlife vascular risk and AD biomarkers with subsequent cognitive decline.
Neurology 2020 September 29
OBJECTIVE: To determine whether vascular risk and AD biomarkers have independent or synergistic effects on cognitive decline, and whether vascular risk is associated with the accumulation of AD pathology, as measured by change in biomarkers over time.
METHODS: At baseline, participants (N = 168) were cognitively normal and primarily middle-aged (M = 56.4, SD = 10.9), and had both vascular risk factor status and proximal CSF biomarkers available. Baseline vascular risk was quantified with a composite vascular risk score reflecting the presence or absence of: hypertension, hypercholesterolemia, diabetes, current smoking, and obesity. CSF biomarkers of Aβ1-42 , total tau (t-tau), and phosphorylated tau (p-tau) were used to create dichotomous "high" and "low" AD biomarker groups (based on Aβ1-42 and tau). Linear mixed effects models were used to examine change in a cognitive composite score (M follow-up = 13.9 years) and change in CSF biomarkers (M follow-up = 4.2 years).
RESULTS: There was no evidence of a synergistic relationship between the vascular risk score and CSF AD biomarkers on cognitive decline. Instead, the vascular risk score ( estimate = -0.022, CI = -0.043 to -0.002, p = 0.03) and AD biomarkers ( estimate = -0.060, CI = -0.096 to -0.024, p = 0.001) were independently and additively associated with cognitive decline. In addition, the vascular risk score was unrelated to levels of, or rate of change in CSF Aβ1-42 , t-tau, or p-tau.
CONCLUSIONS: The results of this observational cohort study suggest that vascular risk and biomarkers of AD pathology, when measured in midlife, act along independent pathways, and underscore the importance of accounting for multiple risk factors for identifying cognitively normal individuals at the greatest risk of cognitive decline.
METHODS: At baseline, participants (N = 168) were cognitively normal and primarily middle-aged (M = 56.4, SD = 10.9), and had both vascular risk factor status and proximal CSF biomarkers available. Baseline vascular risk was quantified with a composite vascular risk score reflecting the presence or absence of: hypertension, hypercholesterolemia, diabetes, current smoking, and obesity. CSF biomarkers of Aβ1-42 , total tau (t-tau), and phosphorylated tau (p-tau) were used to create dichotomous "high" and "low" AD biomarker groups (based on Aβ1-42 and tau). Linear mixed effects models were used to examine change in a cognitive composite score (M follow-up = 13.9 years) and change in CSF biomarkers (M follow-up = 4.2 years).
RESULTS: There was no evidence of a synergistic relationship between the vascular risk score and CSF AD biomarkers on cognitive decline. Instead, the vascular risk score ( estimate = -0.022, CI = -0.043 to -0.002, p = 0.03) and AD biomarkers ( estimate = -0.060, CI = -0.096 to -0.024, p = 0.001) were independently and additively associated with cognitive decline. In addition, the vascular risk score was unrelated to levels of, or rate of change in CSF Aβ1-42 , t-tau, or p-tau.
CONCLUSIONS: The results of this observational cohort study suggest that vascular risk and biomarkers of AD pathology, when measured in midlife, act along independent pathways, and underscore the importance of accounting for multiple risk factors for identifying cognitively normal individuals at the greatest risk of cognitive decline.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app